Clinical trials: Umbilical Cord Blood Transplant
Aplastic Anemia
Study of Fludarabine + Cyclophosphamide + TBI Conditioning Regimen for Double Units Cord Blood Transplantation(CBT)in Severe Aplastic Anemia(SAA)
Severe aplastic anemia is a fatal disease and patients without HLA matched siblings need alternative treatment option. Cord blood transplantation (CBT) has become an alternative treatment means in various diseases, but it has not…
- Trial name
- NCT00881933
- Testing
- Cyclophosphosphamide, TBI
- Where
- South Korea
- Volunteers
- 5 people
- Sponsor
- The Korean Society of Pediatric Hematology Oncology
Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies
This phase I multicenter feasibility trial is studying the safety and potential efficacy of infusing ex vivo expanded cord blood progenitors with one unmanipulated umbilical cord blood unit for transplantation following…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT00343798
- Testing
- cyclophosphamide, fludarabine phosphate, cyclosporine
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Fred Hutchinson Cancer Center
Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL)
Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM
A Study Evaluating the Safety and Efficacy of Transplantation of a single cord blood unit (CBU) of NiCord®, umbilical cord blood-derived Ex Vivo Expanded Stem and Progenitor Cells in Patients with Hematological Malignancies.
- Conditions
- Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
- Trial name
- NCT01816230
- Testing
- NiCord®
- Where
- 15 sites in United States, Italy and 3 more
- Volunteers
- 36 people
- Sponsor
- Gamida Cell ltd
Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
Cord Blood Transplant in Adults With Blood Cancers
Cord blood transplants (CBT) are a standard treatment for adults with blood cancers. MSK has developed a standard ("optimized") practice for cord blood transplant (CBT).
- Conditions
- Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndromes (MDS)
- Trial name
- NCT05884333
- Testing
- Conditioning Chemotherapy, Cord blood graft
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Myeloid Leukemia, Stem Cell Transplantation
GRanulocyte Augmented Cord Blood Transplantation for Poor Risk leukaEmia
Allogeneic stem cell transplantation is the only potentially curative therapy for patients with high-risk Acute Myeloid Leukaemia, but relapse is common and remains the leading cause of death.
- Conditions
- Acute Myeloid Leukemia, Stem Cell Transplantation, Stem Cell Transplantation, Hematopoietic, Cord Blood Stem Cell Transplantation
- Trial name
- GRACE (NCT07372885)
- Testing
- Cord blood transplantation + conditioning + granulocytes of variable days according to study design
- Where
- 3 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- University of Manchester
Sickle Cell Disease, Beta Thalassemia
Stem Cell Transplant in Sickle Cell Disease and Thalassemia
The primary purpose of this study is to see if giving lower doses of chemotherapy (moderately ablative) will result in successful bone marrow replacement without as severe side-effects but with permanent control of the disease.
- Trial name
- NCT00408447
- Testing
- Busulfan, Fludarabine, Alemtuzumab
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Columbia University
CML, AML
Umbilical Cord Blood Transplant for Hematological Malignancies
This protocol will enroll subjects with advanced hematologic malignancies who do not have a suitable related or unrelated donor to undergo a Stem Cell Transplant.
- Conditions
- CML, AML, MDS, ALL
- Trial name
- UCB (NCT00891592)
- Testing
- Ex Vivo CD3/CD28 costimulated Umbilical Cord Blood T cells, Observation Arm
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Pennsylvania
Leukemia
A Study Comparing Single Versus Double Umbilical Cord Blood Transplantation in the Young With Acute Leukemia Remission
Unrelated cord blood transplantation (UCBT) has been used for several years when there is no HLA identical sibling or unrelated donor.Since the recent publication of encouraging results after transplantation of two UCB units, the…
- Trial name
- NCT01067300
- Testing
- Transplantation of unrelated cord blood unit(s)
- Where
- France
- Volunteers
- 198 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Chronic Myeloproliferative Disorders, Leukemia
Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Umbilical cord blood transplantation may be able to replace cells destroyed by chemotherapy.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00054236
- Testing
- anti-thymocyte globulin, filgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Case Comprehensive Cancer Center
Hematologic Neoplasms
Umbilical Cord Blood Stem Cell Transplantation in Adults With Advanced Blood Disorders or Cancer
Umbilical cord blood is an important source of stem cells and can be used to treat blood and immune system disorders and certain types of cancer.
- Trial name
- NCT00312429
- Testing
- Stem Cell Transplantation
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Duke University
Hematopoietic Stem Cell Transplantation, Malignant Hematological Diseases
TFBC Combined With UCBT in the Treatment of High-risk Malignant Hematological Diseases
High-risk malignant hematological diseases refer to malignant hematological diseases, mainly include various types of leukemia, lymphoma, and multiple myeloma, with very poor prognoses, very short survival, and unsatisfactory…
- Trial name
- NCT05929092
- Testing
- Umbilical Cord Blood Transplantation
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Acute Graft Versus Host Disease
Evaluation of Umbilical Cord-Derived Wharton's Jelly Stem Cells for the Treatment of Acute Graft Versus Host Disease
This study evaluates the safety and effectiveness of two different doses of umbilical cord derived, ex-vivo cultured and expanded Wharton's jelly mesenchymal stem cells (MSCTC-0010) in the treatment of acute Graft versus Host…
- Trial name
- NCT03158896
- Testing
- MSCTC-0010 Dose Escalation
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Kansas Medical Center
ALS (Amyotrophic Lateral Sclerosis)
Unrelated Umbilical Cord Blood Transplantation for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS) is a rapidly progressive and fatal neurodegenerative disorder. Its global prevalence is approximately 0.73-1.89 per 100,000 individuals.
- Trial name
- NCT07539662
- Testing
- Mobilization Regimen, Conditioning Regimen, GVHD Prophylaxis
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Unspecified Childhood Solid Tumor, Protocol Specific
Busulfan, Melphalan, and Antithymocyte Globulin Followed By Umbilical Cord Blood Transplant in Treating Young Patients With Refractory or Relapsed Malignant Solid Tumors
RATIONALE: Giving chemotherapy before a donor umbilical cord blood stem cell transplant helps stop the growth of tumor cells. It also helps stop the patient's immune system from rejecting the donor's stem cells when they do not…
- Trial name
- NCT00436761
- Testing
- anti-thymocyte globulin, graft-versus-tumor induction therapy, sargramostim
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Milton S. Hershey Medical Center
Hematologic Malignancies
Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies
This is a phase II study to assess the day 180 event free and overall survival after administration of a specified combination of fludarabine, busulfan, Total Body Irradiation (TBI), and thymoglobulin reduced intensity…
- Trial name
- NCT01622556
- Testing
- Fludarabine, Busulfan, Thymoglobulin
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Virginia
Spinal Cord Injuries
Umbilical Cord Blood Mononuclear Cell Transplant to Treat Chronic Spinal Cord Injury
The purpose of this study is to investigate the feasibility, safety, efficacy and optimal dose of umbilical cord blood mononuclear cell transplant in the treatment of chronic spinal cord injuries.
- Trial name
- NCT01354483
- Testing
- Umbilical Cord Blood Mononuclear Cell, Methylprednisolone, Lithium Carbonate Tablet
- Where
- China
- Volunteers
- 20 people
- Sponsor
- China Spinal Cord Injury Network
Patients With Advanced Lymphoid Malignancies in the Absence of an HLA Identical or Mismatch Donor
Cord Blood Transplantation in Patients With Advanced Lymphoid Malignancies
Indication: Patients with advanced lymphoid malignancies in the absence of an HLA identical or mismatch donor. Objectives: Overall survival at one year. Efficacy >60%, rejection rate <20%.
- Trial name
- LYMPHCORD (NCT01966510)
- Testing
- Cord Blood Transplantation
- Where
- France
- Volunteers
- 19 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Allogeneic Stem Cell Transplantation
Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Mesenchymal Stem Cells
A pilot study to assess the feasibility of unrelated umbilical cord blood transplantation with coinfusion of third-party mesenchymal stem cells after myeloablative or nonmyeloablative conditioning in patients with hematological…
- Trial name
- NCT01092026
- Testing
- cord blood transplantation
- Where
- Belgium
- Volunteers
- 11 people
- Sponsor
- Universitair Ziekenhuis Brussel
Inherited Metabolic Disorders (IMD)
A Follow-up Study in Patients With Inherited Metabolic Disorders (IMD) Who Underwent Hematopoietic Stem Cell Transplantation (HSCT) With MGTA-456
A follow-up study to evaluate the safety and clinical outcomes of patients with inherited metabolic disorders (IMD) who have undergone hematopoietic stem cell transplantation (HSCT) with MGTA-456
- Trial name
- IMD-002 (NCT04008849)
- Testing
- Safety and efficacy assessments
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Magenta Therapeutics, Inc.
Aplastic Anaemia
Conditioning Regimen Containing Low-Dose ATG for the Treatment of AA Receiving sUCBT
To evaluate the safety and efficacy of Single Umbilical Cord blood transplantation (sUCBT) containing low dose ATG based conditioning regimen in the treatment of Aplastic Anemia (AA)
- Trial name
- NCT07885982
- Testing
- Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®)
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Anhui Provincial Hospital